Page 3 - Asco Gi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Asco gi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Asco Gi Today - Breaking & Trending Today

FOLFOXIRI Plus Bevacizumab Use Rises Over Time in mCRC

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger. ....

Flatiron Health Electronic , Flatiron Health Electronic Record Derived , Asco Gi , Metastatic Colorectal Cancer ,

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization. ....

Riccardo Lencioni , Department Of Surgery , Critical Area Pathology , Druvalumab And Bevacizumab Plus Tace , Hepatocellular Carcinoma , Gastrointestinal Cancer , Gi Cancer , Asco Gi , Transarterial Chemoembolization , Phase 3 Emerald 1 Trial , 2024 Gastrointestinal Cancers Symposium , Università Di Pisa ,

177Lu-Dotatate Prolongs PFS vs High-Dose Octreotide in GEP-NETs

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors. ....

Advanced Accelerator , 177lu Dotatate , Gep Nets , Gastroenteropancreatic Neuroendocrine Tumors , Neuroendocrine Tumors , Lutetium Lu 177 Dotatate , Somatostatin Analog , Phase 3 Netter 2 Trial , 2024 Gastrointestinal Cancers Symposium , Asco Gi , Simron Singh , Sunnybrook Health Sciences Centre ,

Nivolumab/Chemo Combination Sustains Survival Improvement in Gastric/GEJ Cancers

Nivolumab plus chemotherapy improved PFS and OS vs chemotherapy alone in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, according to 4-year data from the phase 3 CheckMate 649 study. ....

Kohei Shitara , Gastrointestinal Oncology , National Cancer Center Hospital East , Nivolumab Plus Chemotherapy , Gastric Cancer , Gastroesophageal Junction Cancer , Esophageal Adenocarcinoma , Phase 3 Checkmate 649 Study , Asco Gi ,

Neoadjuvant Camrelizumab/Chemo Combo Shows Clinical Activity in Locally Advanced ESCC

Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma. ....

Department Of Thoracic Surgery , Union Medical College , Chinese Academy Of Medical Sciences , National Cancer Center Hospital , Thoracic Surgery , National Cancer , Cancer Hospital , Chinese Academy , Medical Sciences , Peking Union Medical College , Neoadjuvant Camrelizumab , Camrelizumab Plus Chemotherapy , Locally Advanced Escc , Esophageal Squamous Cell Carcinoma , La Escc , Phase 3 Escort Neo Ncces01 Trial , Asco Gi , 2024 Gastrointestinal Cancers Symposium , Yin Li ,